Five times in a row! Medicilon was shortlisted in the "2022 China CXO Enterprises Top 20 List"

On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released. Shanghai Medicilon Inc. was once again shortlisted in the "China CXO Enterprises Top 20 List".

Being on the list for five consecutive times is a high affirmation and praise from industry authorities for the comprehensive strength of Medicilon's one-stop biopharmaceutical preclinical R&D service platform. It is also the recognition and encouragement of the sustainable development of Medicilon in the future!

2022 China CXO Enterprises Top 20 List.webp

"China's Top 100 Pharmaceutical Industry List Series" is initiated and hosted by Menet.com.cn, a leading platform for China's pharmaceutical and health information. It aims to set a benchmark for china pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand effectiveness, demonstrate the excellence of the pharmaceutical brand industry, and guide the steady, rapid and sustainable development of the pharmaceutical and health industry. This list is selected from the two most important factors, innovation and professional promotion. The selection process has received high attention and active participation from professional research institutions, industry experts and colleagues, which shows its professionalism and authoritative.

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

On July 20, 2020, DAC Biotech’s new ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

阅读全文

Shanghai Medicilon Inc.

搜索此博客